Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arvinas, Inc. - Common Stock
(NQ:
ARVN
)
11.52
+0.50 (+4.54%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arvinas, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Arvinas Appoints Jared Freedberg as General Counsel
January 16, 2024
Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4)
From
Arvinas Inc.
Via
GlobeNewswire
Expert Outlook: Arvinas Through The Eyes Of 9 Analysts
↗
December 19, 2023
Via
Benzinga
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
December 08, 2023
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings.
Via
Benzinga
Analyst Ratings for Arvinas
↗
November 13, 2023
Via
Benzinga
Analyst Expectations for Arvinas's Future
↗
October 23, 2023
Via
Benzinga
Where Arvinas Stands With Analysts
↗
September 07, 2023
Via
Benzinga
Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday
↗
December 08, 2023
U.S. stocks traded mostly higher, with the Dow Jones index gaining more than 40 points on Friday.
Via
Benzinga
Topics
Stocks
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
December 06, 2023
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.
Via
Benzinga
7 Analysts Have This to Say About Arvinas
↗
August 14, 2023
Via
Benzinga
Barclays Maintains Overweight Rating for Arvinas: Here's What You Need To Know
↗
August 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
December 06, 2023
Via
Benzinga
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday
↗
December 06, 2023
U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday.
Via
Benzinga
Topics
Stocks
Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer Candidate
↗
December 06, 2023
Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) released clinical data for vepdegestrant (ARV-471) in combination with
Via
Benzinga
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
November 28, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Why Arvinas (ARVN) Shares Are Seeing Blue Skies
↗
November 27, 2023
Arvinas Inc (NASDAQ: ARVN) shares are trading higher by 11.2% to $24.32 Monday morning after the company announced an oversubscribed $350 million private placement.
Via
Benzinga
Arvinas Announces Oversubscribed $350 Million Private Placement
November 27, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
↗
November 14, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter...
Via
Benzinga
Topics
Stocks
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
November 02, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
October 24, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
October 22, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
October 18, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023
October 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
October 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
September 01, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
July 31, 2023
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP)
From
Arvinas Inc.
Via
GlobeNewswire
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
July 06, 2023
Collaboration expands Carrick’s clinical-stage Oncology program
From
CARRICK THERAPEUTICS LIMITED
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today